ABSTRACT-The effects of injection of substance P (SP) into the hypothalamic supraoptic vasopres sinergic nucleus (SON) in water-loaded and ethanol-anesthetized rats were examined. 
Substance P (SP), a member of the tachykinin family of bioactive peptides, is suggested to be a neurotransmit ter or a neuromodulator in the central and peripheral nervous system (1 3). Immunohistochemical studies have shown that SP terminals are found not only in the spinal cord (4) and the substantia nigra (5) , but also in the hypothalamus (6, 7) . Therefore, the involvement of SP in physiological functions in the hypothalamus such as stimulation of arginine-vasopressin (AVP), growth hor mone and prolactin release has been suggested (8 10) .
The hypothalamic supraoptic nucleus (SON), as well as the paraventricular nucleus (PVN), contains cell bodies of vasopressinergic neurons that synthesize and release AVP. Stimulation of vasopressinergic neurons by neuro transmitters and neuromodulators induces a release of AVP, eventually causing antidiuresis through the renal AVP (V2) receptors (11, 12) . By injecting various drugs into the SON or PVN, we have previously shown that cholinergic (13, 14) , adrenergic (15, 16) and enkephaliner gic mechanisms (17, 18) may control the urine outflow through a stimulation of AVP release.
The vasopressinergic cell bodies in the SON or PVN make synaptic contact with SP-containing nerve termi nals (6) . It was demonstrated that intraventricular injec tion of SP induced a prolonged antidiuresis in water-load ed rat (19) and an increase in firing frequency of the SON (20) . However, the effect of SP microinjected directly into the vasopressinergic nuclei on the AVP release remains un clear. In this study, we examined the effects of SP and its analog [D-Pro2, D-Trp'°9]SP on the outflow, osmotic pres sure and AVP level of urine by injection into the SON in water-loaded and ethanol-anesthetized rats. The influ ences of pretreatments with AVP-receptor, SP-receptor and muscarinic receptor antagonists on the SP-induced antidiuresis were also examined. The present data showed that SP causes antidiuresis through the release of AVP.
MATERIALS AND METHODS

Animals and drugs
Male Wistar rats, weighing 280-330 g, were used. (22) . After the urine outflow had reached a constant rate of 0.06-0.10 ml/min, 1 tcl of the drug solu tion was injected through a microsyringe connected to the cannula. Then 2 pl of an artificial cerebrospinal fluid (CSF: 128 mM NaC1, 3.0 mM KCI, 1.2 mM CaC12i 0.8 MM MgC12, 0.65 mM NaH2PO4, 4.8 mM NaHCO3, pH 7.4) was injected at a rate of approx. 0.3 ,pl/min. Effects of drugs on urine outflow were measured at 10-min inter vals and expressed as a percent of the initial control urine outflow. In the experiments to test the effect of pretreat ment with spantide, an SP-receptor antagonist (23) , the first injection of SP was followed by an injection of the an tagonist, and then the second injection of SP was carried out. The injections of the antagonist and SP were carried out after the urine outflow returned to the initial level 
RIA of A VP in urine
Urine was collected via a bladder catheter and stored at 20'C, and measurements were performed within one month. The urine AVP was assayed directly by RIA after diluting the urine 20-100 times by RIA phosphate buffer to eliminate interference of nonspecific substances. The RIA of AVP was performed as previously described (24) . The minimal amount of AVP measurable by the method was approx. 0.063 pg/tube. The inter and intra-assay coefficients of variation were 4.0% and 1.3%, respective ly.
Measurement of blood pressure, heart rate and respira tion rate
Mean blood pressure and heart rate were measured through a cannula inserted into the carotid artery using, respectively, a pressure transducer (MPU-0.5-290-O-III, Nihon Kohden Kogyo Co., Tokyo) and an electrocardio graph (FD-14, Fukuda, Tokyo). Respiration rate was measured via a thermister probe (SR-115S, Nihon Koh den Kogyo Co.) inserted into a tracheal catheter. These three indices were recorded simultaneously on a recti corder (RJG-3004-2, Nihon Kohden Kogyo Co.).
Identification of the sites of cannula insertion
The position of the tip of the cannula, within the SON, was confirmed by the following methods: 1) functionally, by the appearance of an antidiuresis by the injection of depolarizing doses of KC1 (800 nmol) into the SON through the cannula and 2) histochemically, by the locali zation of the site of the tip of the cannula in a group of magnocellular cells in the SON, positively stained by the method of Gomori (25) .
Statistical analyses
Student's t-test was used for statistical analyses of the paired test. The differences were considered significant at P < 0.05. Unless specified, data are expressed as means ±S.E., and n indicates the number of preparations used. The ED50 values and 95010 confidence limit of the ED50 values for SP and its analog were calculated from the dose-effect curves, which were drawn using the least squares method. Effects of SP and its analog on urine outflow Substance P (1 and 5 nmol) microinjected into the SON decreased the urine outflow (Fig. 1a ). An analog of SP, [D-Pro2, D-Trp7'9]SP (1 and 10 nmol) also decreased the urine outflow (Fig. lb) . The urine outflow was usually Effects of spantide on SP-induced antidiuresis Spantide (10 nmol), an SP-receptor antagonist, when injected into the SON, significantly decreased the urine outflow by approx. 38±17% (n=7). This antagonist caused a weak inhibition of the antidiuresis of SP (1 nmol) because the inhibition was observed only at 40 min after the injection, as illustrated in Fig. 3 . The pretreat ment with the antagonist recovered the urine outflow decreased by the injection of SP earlier than injection of SP alone.
Effects of SP on the urine osmotic pressure Table 1 shows the effect of SP on the osmotic pressure of urine, as compared to its effects on urine outflow. The osmotic pressure increased to approx. 300% of the initial control value at 20-30 min after the injection of SP (1 nmol), when the outflow was decreased to a minimal level (approx. 20% of the initial control value). When the urine outflow almost returned to the initial level, at 50-100 min after injection, the osmotic pressure also returned to the initial control value. After an injection of AVP (4 mU) which decreased the urine outflow, the osmotic pres sure increased to approx. 340% of the initial control value. Vehicle (CSF) alone, when injected into the nucleus, affected neither the osmotic pressure nor the urine outflow.
Effects of SP on urine level of A VP
As shown in Table 2 , the level of AVP in the urine was elevated to approx. 70 times the initial control level at 20-30 min after the injection of SP (1 nmol). Although the urine outflow almost returned to the initial control value at 40-70 min after injection of SP, the level of AVP in the urine was significantly higher than the initial control level. After an intravenous injection of AVP (4 mU) which decreased the urine outflow, the urine AVP level was elevated to approx. 100 times the initial level. Vehicle (CSF) alone did not affect the urine AVP level. Table 1 .
Effects of SP and AVP on urine osmotic pressure and urine outflow Table 2 .
Effects of SP and AVP on AVP level in unextracted urine
Inhibition by an A VP receptor antagonist of the anti diureses induced by SP and its analog As shown in Fig (1 nmol, Fig. 5a ). However, atropine sig nificantly inhibited the antidiuresis of [D-Pro2, D-Trp''9] SP (1 nmol). Atropine (300 nmol) alone had no effects on the urine outflow.
Cardiovascular and respiratory effects of SP
Some visceral functions, which may be caused by SP, and which may influence the urine outflow, were moni tored during the experiments. However, no significant changes in blood pressure, heart rate and respiration rate were observed by the injection of SP (1 nmol, n=4) (data not shown). 
DISCUSSION
The present study shows that SP and its analog [D-Pro2, D-Trp7'9]SP, when injected into the SON, induce marked decreases in urine outflow. The time-course of the effects of SP and the analog, which began within 20 min, peak ing at 20 min, and disappearing at 60 80 min after inj ec tion, was comparable to those of drugs such as choliner gic, adrenergic and enkephalinergic agonists which have been previously reported (13 18) . The relatively slow time-course of these effects suggests that the effects are mediated through hormonal pathways such as a release of AVP rather than neuronal pathways. When the ED50 values for these agonists inducing antidiureses were com pared, SP (0.4 nmol) and the analog (0.9 nmol) were much more potent than ACh (80 nmol, ref. Injection of a 1-11 volume of the effective dose of anti diuretic agonists, such as oxotremorine or NA, at a dis tance of 1 mm outside the SON, did not induce any sig nificant effects on the urine outflow. The diffusion range after microinjection of methylene blue (1 pl) demonstrat ed that the distance of simple diffusion of microinjected SP was less than 1 mm. These results suggest that SP acts directly on the SON.
As the effect of SP on the urine outflow was inhibited by a pretreatment with the SP-receptor antagonist span tide (23) , SP regulates the urine outflow through an SP receptor. Although Buck and Shatzer (26) suggested that spantide is an antagonist with preference for the neuro kinin-1 receptor, the receptor selectivity of the antagonist is still in question (27 29) . On the other hand, the finding that the selective neurokinin-3 receptor agonists stimulate the AVP release (30, 31) indicates the possible involve ment of the central neurokinin-3 receptors in the AVP re lease induced by tachykinins. Therefore, the weak inhibi tion by spantide on SP-induced antidiuresis in this study may be due to the receptor selectivity of this antagonist. As an alternative reason, the antagonistic effect of span tide may reduce at 60-80 min after injection of the an tagonist, since the duration of spantide II is relatively short (approx. 60 min, ref. 32). Further studies using neu rokinin receptor subtype-specific agonists or antagonists are required to clarify the receptor subtype involved in the AVP release.
The SP-induced decrease in the urine outflow was as sociated with increases in the osmotic pressure (threefold) and AVP level (70-fold) of urine. This effect on osmotic pressure was similar to those induced by ACh, NA and opioids (13) (14) (15) (16) (17) (18) . The increase in urine AVP level prob ably reflects an increase in plasma AVP level (24, 33) . The urine AVP level can be measured by radioimmunoassay without prior extraction. The interference by a non specific substance which was observed in the plasma AVP extract can be eliminated by dilution of the urine. When the urine was diluted to 20-100 volumes with an assay buffer, the relationship between urine AVP level and dilu tion ratio was nearly linear. At 40-70 min after injection of SP when the urine outflow and osmotic pressure returned to the initial level, the urine AVP level was still elevated. The time course of the effect of SP on urine out flow and osmotic pressure may be different from that on AVP level. In addition, the decrease in urine outflow by SP was almost completely blocked by a pretreatment with an intravenous injection of the AVP (V,V2)-receptor an tagonist, which has a higher sensitivity for the renal V2 receptors (34) . These results suggest that the injection of SP into the SON stimulates the AVP release. In the SON, SP may enhance the AVP release from neurohypophysis and reabsorption of water from the kidney by stimulating the renal V2-AVP receptors. This study indicates the pos sibility that in addition to the cholinergic, adrenergic and opioid peptidergic neurons, SP-containing neurons also play important roles in the regulation of AVP release.
Synthetic analogs of SP with antagonistic properties have been developed. [D-Pro2, D-Trp7'9]SP used in this study has also a specific antagonistic activity on smooth muscle preparations (35) and neurons in the locus coeruleus (36) . In this study, the two SP analogs, [D-Pro2, D-Trp7'9]SP and spantide, injected into the SON, caused decreases in urine outflow, like SP. The former analog has a similar potency to SP, while the latter analog was less potent than SP. Since the effect by the former analog was abolished by a pretreatment with an intravenous injec tion of the AVP (V1V2)-receptor antagonist, this analog may stimulate the AVP release. The antagonistic analog may act as an agonist in the SON as already demonstrated in the locus coeruleus (37) .
In this study, however, [D-Pro2, D-Trp7'9]SP (1 nmol) did not inhibit the SP (1 nmol)-induced antidiuresis, sug gesting that the antagonistic activity of the SP analog is less potent in the SON. Therefore, much higher doses of the SP analog may be needed to exert the antagonistic effect against SP. Since high doses of [D-Pro2, D-Trp7'9] SP induce a neurotoxic effect (38) , further studies are necessary to elucidate the antagonistic effect of the SP ana log.
It is unknown why atropine inhibits the [D-Pro2, D Trp7'9] SP-induced antidiuresis, but not the SP-induced effect. The inability of atropine to inhibit the SP-induced effect was unexpected, since this finding differs from the demonstration that SP evoked the ACh release from spi nal neurons (39) . One possible explanation of this finding is that the effect of [D-Pro2, D-Trp7'9]SP may be mediated by a cholinergic mechanism in the SON. However, fur ther studies are needed to investigate the difference in mechanisms between them.
One nanomole of SP injected into the SON did not affect cardiovascular functions such as blood pressure, heart rate and respiratory rate, although it induced marked antidiuresis. This finding indicates the effect of SP on urine outflow is not due to the change in hemody namics. Some investigations have shown that SP affected cardiovascular function even by intracerebroventricular injection or microinjection into the nucleus tractus soli tarii (10, 31, 40 42) . The difference in the results between these studies and the present study may be due to a differ ence in the site of injection.
In conclusion, the results suggest that SP and [D-Pro2, D-Trp7'9]SP, injected into the SON, stimulate the AVP re lease through the activation of SP receptors, inducing the antidiureses. The effect of the SP analog may be partly mediated through a different mechanism from that of SP.
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